|
Volcano Corporation
Announces Presentations at American College of Cardiology 2011
|
 |
 |
|
April 2, 2011 --
San Diego -- Volcano Corporation (NASDAQ: VOLC) today
announced its participation in the 60th Annual Scientific Session
of the American College of Cardiology (ACC) from April 2nd
to April 5th, 2011 in New Orleans.
"Volcano continues to lead
the industry in partnering with physicians to deliver Precision
Guided Therapy to patients worldwide," commented Scott Huennekens,
President and CEO of Volcano. "Our comprehensive suite of guidance
technologies provides the precise insight that physicians need
to make treatment decisions that result in a truly personalized
treatment path for their patients. We are excited to highlight
our innovative devices that have already impacted more than
one million patients, contributing to their chances of better
outcomes, shorter hospital stays, lower costs, and, typically,
a higher quality of life." |
Product Innovations
Volcano will highlight its suite of precision
guided therapy technologies, which includes integrated cath lab systems,
coronary and peripheral
IVUS catheters, and physiology guide wires measuring both pressure
and flow. These products, which are all available for sale in the
U.S. and/or Europe, include:
- The PrimeWire PRESTIGE™, the next
generation Fractional Flow Reserve (FFR) wire with a familiar
frontline tip, better
torque and more support for challenging lesions;
- The Eagle Eye® Platinum, the #1 digital IVUS catheter in
the world, which provides exceptional deliverability, the convenience
of radiopaque markers,
and three imaging modalities including grayscale IVUS, VH® IVUS and ChromaFlo®;
- The VIBE® RX Vascular Imaging Balloon
Catheter, which can quickly access, prepare, and assess challenging
lesions and provide
precise, targeted balloon
dilatation with immediate confirmation of interventional results; and
- The s5™/s5i™ 3.2.1 software,
which streamlines the workflow for both IVUS and FFR procedures
and is compatible with
more than 3,700 Volcano
systems installed worldwide.
All products will be available for demonstration at Booth #4034.
Volcano's technology will also be on display in other booths, including
GE Healthcare, Siemens Healthcare, Philips Healthcare, and Toshiba
America Medical Systems. In addition, Volcano will highlight its
extensive pipeline of imaging and therapy products still in development,
including Optical Coherence Tomography (OCT), Micro Catheters,
and Forward Looking Imaging including IVUS and ICE applications.
"Volcano is focused on providing quality guidance solutions
for our customers, and allowing physicians to choose which tool is
the most appropriate for that particular patient's presentation," added
Joe Burnett, Volcano's Executive Vice President of Marketing. "This
year at ACC, we are focusing much of our training and education efforts
around bifurcation disease, which remains a large, unmet clinical
need, with repeat revascularization rates routinely higher than 10%.
Physicians are continuously looking for ways to improve the level
of care they provide in these complex lesions, and there are more
than 20 presentations at the ACC this year focused on this topic.
We believe that by assessing bifurcation lesions with tools like
IVUS and FFR, a physician can more precisely decide on their main
branch and side branch strategy, guide the placement of the stent,
and then confirm the function of that side branch while the patient
is still on the table. Volcano is the only company that can provide
both of these technologies on the same product platform seamlessly
integrated into the Cath Lab for ease of use and prompt diagnostics."
About Volcano Corporation
Volcano Corporation is revolutionizing
the medical device industry with a broad suite of technologies that
make imaging and therapy
simpler, more informative and less invasive. Our products empower
physicians around the world with a new generation of analytical tools
that deliver more meaningful information - using sound and light
as the guiding elements. Founded in cardiovascular care and expanding
into other specialties, Volcano is changing the assumption about
what is possible in improving patient outcomes by combining imaging
and therapy together.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995.
Any statements in this release that are not historical facts may
be considered "forward-looking statements." including statements
regarding the potential benefits of the products and procedures described
above, further development and expansion, regulatory approval, commercial
release and market adoption of the company's technology, and the
impact of clinical and other technical data. Forward-looking statements
are based on management's current expectations and are subject to
risks and uncertainties which may cause Volcano's results to differ
materially and adversely from the statements contained herein. Some
of the potential risks and uncertainties that could cause actual
results to differ include the pace and extent of market adoption
of the company's products and technologies, growth strategies, timing
and achievement of product development milestones, outcome of ongoing
litigation, the impact and benefits of market development, product
introductions, unexpected new data, safety and technical issues,
market conditions, and other risks inherent to medical device development
and commercialization. These and additional risks and uncertainties
are more fully described in Volcano's filings made with the Securities
and Exchange Commission, including our recent annual report on Form
10-K. Undue reliance should not be placed on forward-looking statements
which speak only as of the date they are made. Volcano undertakes
no obligation to update any forward-looking statements to reflect
new information, events or circumstances after the date they are
made, or to reflect the occurrence of unanticipated events.
Source: Volcano
Corporation
|
